Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
TED Market Dynamics | Explore Viridian's position in the evolving thyroid eye disease treatment landscape, challenging established players with innovative therapies |
Pipeline Promise | Delve into VRDN-001's potential as a game-changer for TED treatment, with pivotal Phase III results expected to shape Viridian's future |
Financial Health | Discover Viridian's robust financial position, boasting a cash runway into 2027 and a remarkable current ratio of 18.55 |
Growth Trajectory | Analyst price targets range from $22 to $61, reflecting optimism about Viridian's potential in the expanding TED market and beyond |
Metrics to compare | VRDN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRDNPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.7x | −5.4x | −0.6x | |
PEG Ratio | −0.36 | −0.01 | 0.00 | |
Price/Book | 2.8x | 2.2x | 2.6x | |
Price / LTM Sales | 4,857.7x | 1,778.4x | 3.1x | |
Upside (Analyst Target) | 115.7% | 145.1% | 51.7% | |
Fair Value Upside | Unlock | −5.7% | 7.5% | Unlock |